Is the Chinese version of HPV vaccine coming? Seventy percent of global stock shortages are contributed by Chinese Enterprises

category:Finance
 Is the Chinese version of HPV vaccine coming? Seventy percent of global stock shortages are contributed by Chinese Enterprises


Seventy percent of the global gap

This disease is not only preventable, but also curable. The premise is early diagnosis and early treatment. Early diagnosis and early treatment can save more than 90% of cervical cancer patients. Qiao Youlin, member of the WHO HPV Vaccine Expert Advisory Committee, former vice-chairman of the Expert Committee on Early Diagnosis and Treatment of Cancer of the Department of Disease Prevention and Control of the Ministry of Health, and head of the Expert Group on Cervical Cancer, told First Finance and Economics.

Doctor Taulina, who worked for the Center for Disease Control and Prevention in Shanghai for 15 years, also said in an interview: It is not necessary for everyone to focus on the nine-valent HPV vaccine. In fact, the two-valent and four-valent HPV vaccines have good preventive effect. Because of the current shortage of nine-valent vaccines, many women have to stand in line to shake the horn, but studies have shown that the immunogenicity of HPV vaccines decreases with age. Therefore, delaying vaccination time in order to queue up for nine-valent vaccines is actually an unpaid behavior.

It is not only China that needs HPV vaccine, but there are only two pharmaceutical companies on the market: the bivalent vaccine of Glaxosin and the tetravalent and ninth-valent vaccine of Mosadong. Divalent, tetravalent and nine-valent HPV vaccines have significant preventive effects on 70%, 70% and 92% of cervical cancer, respectively.

Considering the high health economics value of HPV vaccine, more countries or regions will incorporate it into national immunization planning in the future. But in 2018, the global HPV immunization supply capacity was only 30 million doses, about one third of the total demand. According to estimates, there are about 356 million people who need to be vaccinated with HPV vaccine in China. According to the data of the Chinese Peoples Procuratorate, more than 38 million HPV vaccines were wholesaled in 2018, and 12.16 million HPV vaccines were wholesaled in 2018, which is far from in line with the market demand.

Prices are also a major concern for the Chinese public. According to the published price of Beijing CDC, the bivalent vaccine is 580 yuan (RMB)/injection, 798 yuan (IV)/injection and 1298 yuan (IX)/injection. In order to make the cheap HPV vaccine available to the Chinese people and solve the supply problem, many Chinese enterprises have invested in the HPV vaccine camp.

As the largest buyer of vaccines in the world, the Global Alliance for Vaccines (GAVI) procures 60% of global vaccine production annually. Seth Berkley, chief executive of the alliance, said in an interview with First Financial Journalist recently that GAVI plans to include cervical cancer vaccine (HPV vaccine) in the next five years, hoping that more Chinese manufacturers can pass WHO pre-certification. If Chinese enterprises can produce in large quantities, they will provide cheaper HPV vaccines for China and developing countries. Seth Berkeley said.

China Opens the Gate for the Development of the Third Generation Cervical Cancer Vaccine

The price of a vaccine represents how much immunity it can produce. Scientists from our country have been the first to open the door to the development of 20-valent cervical cancer vaccine.

On December 18, 2018, Xiamen University, Director of National Center for Diagnostic Reagents and Vaccine Engineering, Xiamen University, published a paper entitled Rational ldesign of atriple-type human papillomavirus vaccines by compromising viral-type specificity, based on human papillomavirus (HPV). The type-specific structural basis of papillomavirus (HPV) and the relationship between molecular evolution and structural conservatism of HPV genotypes were studied. A chimeric virus-like particle (VLP) was designed for three types of HPV to simultaneously produce cross-protection effects. This study aims to develop a broader spectrum covering all high-risk HPV genotypes. The key technology foundation of HPV vaccine generation is laid, which provides a new idea for the development of multi-type virus vaccine.

This paper is of great significance for the development of 20-valent cervical cancer vaccine.

It is understood that the nine-valent cervical cancer vaccine, which has been marketed, has the broadest scope of protection. It can prevent seven high-risk and two low-risk HPV infections, that is, about 90% of cervical cancer, but the remaining 10% of cervical cancer incidence also needs to be prevented.

After six years of research, Professor Xia Ningshaos team has made breakthroughs in key technologies and developed a highly effective vaccine that can protect more HPV types with fewer virus-like particles.

They divided 20 cancer-related HPV genotypes (including 18 high-risk and 2 low-risk types) into seven groups according to their genetic relationships, and found that the closely related HPV genotypes shared a common skeleton and different external details.

The team designed a complex chimeric virus-like particle using a new structural vaccine approach. It integrates the ring characteristics of three types of HPV virus particles (HPV33, HPV58 and HPV52), so that the former can only simulate the morphology of one type of HPV, and becomes a virus-like particle that can simulate the morphology of three types of HPV, that is, a new sphere has the characteristics of the previous three spheres.

Our research paves the way for the development of a new generation of HPV vaccine. It shows that only seven chimeric viroid particles are needed to prevent cervical cancer caused by 20 HPV types. Xia Ningshao said.

The technology of Ningshao Team in Xiamen Wantai began to transform. Recently, GlaxoSmithKline and Yangshengtang Xiamen Wantai signed a cooperative agreement to jointly develop a new generation of human papillomavirus (HPV) vaccine based on innovative antigen technology from Xiamen University and adjuvant system of GlaxoSmithKline (GSK).

According to the agreement, Wantai Xiamen will build a vaccine production line in Haicang, Xiamen, which meets the standards of China, the United States, the European Union and WHO. It will supply several types of HPV vaccine antigens to GSK. GSK will combine these antigens with GSKs patented AS04 adjuvant to develop new HPV vaccines and implement them worldwide, including Europe and the United States. It is now commercialized.

For this collaboration, Glaxo says authoritative data from Scotland show that GSKs AS04 adjuvant system provides clinical protection regardless of HPV type. This encourages GSK scientists to find partners with which to collaborate in the development of the next generation of adjuvant HPV vaccine. Wantai was chosen on the basis of their commitment to HPV and their continued research and development in this field. The combination of new antigen technology antigen and AS04 adjuvant system to produce new HPV vaccine has strong rationality. Zhang Jun, a professor at the School of Public Health, Xiamen University, told First Finance and Economics that combining top-notch production technology of HPV vaccine antigen with top-notch vaccine adjuvant technology could further improve the immunogenicity of vaccines and the broad spectrum of protective antibodies, thus making it possible to reduce the number of vaccinations on the one hand. On the other hand, it is possible to prevent more types of cervical cancer-related HPV infection and cervical cancer. In addition, for the first time, Chinas vaccine technology has the opportunity to go to the center of the world stage and occupy a place in the main battlefield of global vaccine competition. Source: First Financial Responsibility Editor: Zhong Qiming_NF5619

For this collaboration, Glaxo says authoritative data from Scotland show that GSKs AS04 adjuvant system provides clinical protection regardless of HPV type. This encourages GSK scientists to find partners with which to collaborate in the development of the next generation of adjuvant HPV vaccine. Wantai was chosen on the basis of their commitment to HPV and their continued research and development in this field. The combination of new antigen technology antigen and AS04 adjuvant system to produce new HPV vaccine has strong rationality.

Zhang Jun, a professor at the School of Public Health, Xiamen University, told First Finance and Economics that combining top-notch production technology of HPV vaccine antigen with top-notch vaccine adjuvant technology could further improve the immunogenicity of vaccines and the broad spectrum of protective antibodies, thus making it possible to reduce the number of vaccinations on the one hand. On the other hand, it is possible to prevent more types of cervical cancer-related HPV infection and cervical cancer. In addition, for the first time, Chinas vaccine technology has the opportunity to go to the center of the world stage and occupy a place in the main battlefield of global vaccine competition.